What is Roth Capital’s Estimate for BRTX FY2024 Earnings?

BioRestorative Therapies, Inc. (NASDAQ:BRTX) – Roth Capital raised their FY2024 earnings per share estimates for BioRestorative Therapies in a report released on Thursday, November 14th. Roth Capital analyst J. Aschoff now expects that the company will post earnings of ($1.43) per share for the year, up from their prior estimate of ($1.76). The consensus estimate for BioRestorative Therapies’ current full-year earnings is ($1.43) per share. Roth Capital also issued estimates for BioRestorative Therapies’ Q4 2024 earnings at ($0.27) EPS, Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.86) EPS, FY2026 earnings at ($0.83) EPS and FY2027 earnings at $3.43 EPS.

Separately, Roth Mkm upped their price objective on BioRestorative Therapies from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th.

BioRestorative Therapies Stock Performance

Shares of NASDAQ BRTX opened at $1.45 on Monday. The firm’s 50 day moving average price is $1.63 and its 200-day moving average price is $1.60. BioRestorative Therapies has a 52-week low of $1.03 and a 52-week high of $3.67. The company has a market cap of $10.03 million, a PE ratio of -0.95 and a beta of 63.40.

BioRestorative Therapies (NASDAQ:BRTX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.22. BioRestorative Therapies had a negative return on equity of 98.49% and a negative net margin of 2,697.08%. The firm had revenue of $0.23 million during the quarter, compared to analyst estimates of $0.30 million.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.